<DOC>
	<DOCNO>NCT02867280</DOCNO>
	<brief_summary>This prospective multicenter non-randomized control study evaluate efficacy safety treatment Sorafenib ( Nevaxar ) patient hepatocellular carcinoma microvascular invasion radical resection compare conventional therapy .</brief_summary>
	<brief_title>Sorafenib Treatment Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection</brief_title>
	<detailed_description>The study multicenter , non-randomized , open-label , blank control study initiate Investigators . The study population include patient without macroscopic vascular invasion distant metastasis , undergo R0 resection , postoperative pathology confirm hepatocellular carcinoma microvascular invasion ( MVI ) ( BCLC A B stage ; T2 part T3aN0M0 ) . The primary end point study recurrence free survival（RFS）at 2nd postoperative year , secondary end point include postoperative median time recurrence ( TTR ) , 1-year , 3-years , 5-years postoperative recurrence free survival ( RFS ) , 3-years , 5-years postoperative overall survival , safety tolerance sorafenib adjuvant therapy HCC . Patients treatment group start Sorafenib within 4 week hepatectomy doze 400mg per day , last continuously 2 year , disease progression . Patients control group take regular treatment use Sorafenib . Both group forbid receive postoperative anti-cancer therapy adjuvant radiotherapy , chemotherapy TACE . Patients group receive antiviral therapy accord guideline . Chinese traditional medicine nutritional support use without limitation , information concomitant drug need record analysis . Treatment relieve drug relate AEs use need . Patients group treat best clinical practice routine confirm recurrence/metastasis , information treatment need record follow-up till death .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Age 1875 year 2 . Hepatocellular carcinoma confirm pathology 3 . No macroscopic tumor thrombus vascular invasion distant metastasis 4 . R0 resection（clean resection margin macroscopically microscopically） 5 . MVI confirm pathology 6 . ECOG 01 7 . ChildPugh stage A 8 . WBC &gt; 3×10E9/L；HB &gt; 90 G/L；PLT &gt; 50×10E9/L 9 . ALT，AST exceed 5 time upper limit normal value；CRE，TBIL exceed 1.5 time upper limit normal value 1 . Tumor rupture invade adjacent organ 2 . Patients underwent liver transplantation 3 . Past history simultaneously receive anticancer therapy ( TACE , chemotherapy , radiotherapy others）and immune cell infusion therapy 4 . Uncontrolled cardiovascular cerebrovascular diseases 5 . History gastrointestinal bleeding within 6 month 6 . Active infection HBV , HCV 7 . Postoperative complication , suitable take Sorafenib ( long term use drainage due bile leakage , poor wound heal others ) 8 . Confirmed liver cancer recurrence metastasis within 4 week hepatectomy 9 . Poor compliance , adhere regular follow 10 . Diagnosed original malignant tumor HCC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Microvascular invasion</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>hepatocellular carcinoma</keyword>
</DOC>